Close of Accelerated Bookbuild to New Orders
Arecor Therapeutics plc announced the close of its accelerated bookbuild to new orders, following an earlier announcement on September 30, 2026. The company will provide a further update on the results of the placing and the completion timetable. This announcement contains inside information and is for informational purposes only, not constituting an offer or advice regarding securities.
Select text to share a quote on X · sign in to keep highlights & notes in your AREC notes
Arecor Therapeutics plc (AIM: AREC), a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, is pleased to announce that, further to the announcement made at 7:01 a.m. on 30 September 2026 (the Launch Announcement), the Placing has now closed to new orders. A further announcement will be made by the Company in due course confirming the result of the Placing and the timetable to completion.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.